ENDRA Life Sciences Strengthens TAEUS® System Global Intellectual Property Portfolio with Issuance of 6th and 7th European Patents
February 11 2022 - 8:00AM
Business Wire
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of
Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the
European Patent Office (EPO) has issued two new patents to ENDRA,
European Patent No. 3668382 (the ‘382 patent) titled “Method and
System for Estimating Fractional Fat Content of an Object” and
European Patent No. 3661416 (the ‘416 patent) titled “Method for
Estimating Fractional Fat Content of an Object.”
- The ‘382 patent protects ENDRA's method and system for
calculating a fat concentration in the human body with a single
thermoacoustic measurement. The ‘382 patent is related to U.S.
patent 9888879B1 and Chinese patent ZL201880050052.6.
- The ‘416 patent protects ENDRA's method for calculating a fat
concentration in the human body with multiple thermoacoustic
measurements. The ‘416 patent is related to U.S. patent 9888880B1
and Chinese patent ZL201880050042.2.
“These two European patents further strengthen our intellectual
property estate and advance our strategy to develop optimized
hybrid ultrasound and thermoacoustic imaging systems with our
proprietary TAEUS® technology in areas with unmet clinical needs,"
stated ENDRA's Chief Executive Officer, Francois Michelon. "We
continue to enhance our intellectual property portfolio to protect
our technology in priority global markets. Our portfolio currently
stands at 89 assets, which we define as patents issued, filed or in
preparation.”
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology being developed
to visualize tissue like MRI, but at 1/50th the cost and at the
point of patient care. TAEUS® is designed to work in concert with
400,000 cart-based ultrasound systems in use globally today. TAEUS®
is initially focused on the measurement of fat in the liver as a
means to assess and monitor Non-Alcoholic Fatty Liver Disease
(NAFLD) and inflammation (NASH), chronic liver conditions that
affect over one billion people globally, and for which there are no
practical diagnostic tools. Beyond the liver, ENDRA is exploring
several other clinical applications of TAEUS®, including
visualization of tissue temperature during energy-based surgical
procedures. For more information, please visit
www.endrainc.com.
Forward-Looking Statements
All statements in this news release that are not based on
historical fact are "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward- looking statements, which
are based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use
of forward-looking terms such as "believe," "expect," "may,"
"will," "should," "could," "seek," "intend," "plan," "goal,"
"estimate," "anticipate" or other comparable terms. Examples of
forward-looking statements for ENDRA include, among others,
estimates of the timing of future events and achievements, such as
expectations concerning ENDRA's business strategy, which may be
affected by risks related to the impact of COVID-19 on its business
plan, its ability to find and maintain development partners, market
acceptance of its technology and the amount and nature of
competition in its industry, its ability to protect its
intellectual property, and other risks and uncertainties described
in its filings with the Securities and Exchange Commission.
Forward-looking statements involve inherent risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements as a result of various factors
including, among others, our ability to develop a commercially
feasible technology; receipt of necessary regulatory approvals; the
impact of COVID-19 on our business plans; our ability to find and
maintain development partners, market acceptance of our technology
and the amount and nature of competition in our industry; our
ability to protect our intellectual property; and the other risks
and uncertainties described in ENDRA's filings with the Securities
and Exchange Commission. The forward-looking statements made in
this news release speak only as of the date of issuance, and ENDRA
assumes no obligation to update any such forward-looking statements
to reflect actual results or changes in expectations, except as
otherwise required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220201006211/en/
Company Contact: Irina Pestrikova Senior Director,
Finance investors@endrainc.com www.endrainc.com Investor
Relations Contact: Yvonne Briggs LHA Investor Relations (310)
691-7100 YBriggs@lhai.com
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Aug 2024 to Sep 2024
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Sep 2023 to Sep 2024